Arthritis news from FiercePharma
NewsEnbrel gets black-box infection warning
Enbrel's new black box is now official. Wyeth and Amgen have put the final touches on a Read more...
SPOTLIGHT: Rituxan falls short in lupus trial
In a big disappointment for Genentech and Biogen Idec, Rituxan failed its late-stage test against lupus. Already approved for non-Hodgkins lymphoma and rheumatoid arthritis treatment, Rituxan might Read more...
SPOTLIGHT: Wyeth sales boosted by Enbrel
Despite major erosion in sales of its heartburn blockbuster Protonix, Wyeth managed to beat Wall Street's expectations for first-quarter earnings, posting a $1.2 billion profit on a 6 percent Read more...
SPOTLIGHT: Insurers hike co-pays for expensive meds
Health insurers are passing on the high cost of some meds to patients, asking them to pay up to one-third the price of expensive drugs; the policies affect drugs for such serious illnesses as Read more...
SPOTLIGHT: Enbrel gets 'black box' infection warning
Amgen and Wyeth added a "black box" warning to their Enbrel arthritis drug to caution doctors and patients about the risk of infection, including tuberculosis. Read more...
Earnings from Schering, Sanofi, Teva
It's an earnings kind of day today, with two of the brand-name biggies reporting, plus the leading generics maker. Here are the results:Schering-Plough reported a $3.4 billion loss for the fourth Read more...
Roche sales surpass Novartis'
Eat dust, Novartis. Roche just posted sales of $42.2 billion, $2.4 billion more than its Swiss rival's $39.8 billion. Strong sales of its cancer drugs helped boost profits by 25 percent to $10.48 Read more...
SPOTLIGHT: MabThera aims for new indications
Roche's antibody med MabThera (Rituxan) just aced two trials aimed at expanding uses for the drug: one that pitted MabThera against rheumatoid arthritis and another that used it against adult Read more...
Alzheimer's: A new indication for Enbrel?
For yet another example of the trend toward teaching old drugs new tricks, check out Exhibit E for Enbrel. According to research released today, the anti-rheumatoid arthritis med has shown an Read more...
Amgen reps allege marketing abuse
As if Amgen didn't have enough to worry about with its cash-cow anemia drugs under fire. Now it's not only Read more...
| Press ReleasesPRESS RELEASE: Trubion Pharmaceuticals Shares Plunge After Arthritis Trial Results Trubion Pharmaceuticals Shares Plunge After Arthritis Trial Results SEATTLE, Sept. 10 -- Trubion Pharmaceuticals today announced preliminary analysis of results from a Phase IIb randomized, Read more... PRSS RELEASE: Pozen, AstraZeneca Announce Start of the PN 400 Phase III Program POZEN/AstraZeneca Announce Start of the PN 400 Phase III Program AstraZeneca to Pay an Immediate $30 Million Payment Under Revised Licensing Arrangement CHAPEL HILL, N.C.--(BUSINESS WIRE)--POZEN Read more... |
Get more Arthritis coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight